联合用药治疗溃疡性结肠炎临床疗效(2)
第1页 |
参见附件。
Bai AP,Ouyang Q. Probiotics and inflammatory bowel diseases[J]. Postgrad Med J,2006, 82(968): 376-382.
[3]Chermesh I,Eliakim R. Probiotics and the gastrointestinal tract : Where are we in 2005?[J].World J Gastroenterol,2006,12(6):853-857.
[4]Gionchetti P,Rizzello F,Lammers KM,et al. Antibiotics and probiotics in treatment of inflammatory bowel disease[J].World J Gastroenterol,2006,12(21):3306-3313.
[5]Dotan I,Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action[J]. Curr Opin Gastroenterol,2005,21(4): 426-430.
[6]SANDOR Z DENG X M,KHOMENKO T, et al Altered angiogenic balance in ulcerative colitis: akey to impaired healing[J].Biochem Biophys Res Commun,2007, 350 (1): 147150.
[7]欧阳钦.我国炎症性肠病诊治规范共识意见解读[J].中华消化杂志,2007,27(10):691-692.
[8]潘国宗.溃疡性结肠炎的病因和发病机制[J].现代消化及介入诊疗,2008,13(2):103-105.
[9]Naser SA, Schwartz D, Shafran I. Isolation of Mycobacterium avium subsp paratuberculosis from breast milk of Crohn′s disease patients[J].Am J Gastroenterol,2000,95(4):1094-1095.
[10]Rembacken BJ, Snelling AM, Hawkey PM,et al.Non pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial[J].Lancet,1999,354(9179):635-639.
[11]Gionchetti P, Rizzello F, Lammers KM, et al. Antibiotics and probiotics in treatment of inflammatory bowel disease[J].World J Gastroenterol,2006,12(21):3306-3313.
[12]Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action[J]. Curr Opin Gastroenterol,2005, 21(4):426-430.
编辑/申磊
您现在查看是摘要介绍页,详见PDF附件。